# OnCo record keynote-355 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-355/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-355", "NCT02819518" ;
  schema:name "KEYNOTE-355"@en ;
  schema:description "Established immunotherapy plus chemotherapy as first-line treatment for metastatic triple-negative breast cancer with PD-L1 expression."@en ;
  schema:url <https://onco.cc/trials/keynote-355/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02819518>, <https://doi.org/10.1016/S0140-6736(20)32531-9>, <https://doi.org/10.1056/NEJMoa2202809>, <https://www.nice.org.uk/guidance/ta801> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2016-07-27" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/keynote-119/>, <https://onco.cc/trials/impassion130/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/trials/tropion-breast05/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/>, <https://onco.cc/key-papers/paper-keynote-355-lancet-2020/> .